COVID-19 and cardiovascular diseases

Чазова, И Е; Mironova, Olga Iu.

doi:10.26442/00403660.2020.09.000742

Cited by 11 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[27] According to these studies, the inflammatory process plays a key role in the pathogenesis of heart failure. Dunley et al in the Olmsted County study concluded that the level of (TNF)-α in patients with HF with a preserved ejection fraction was higher and directly correlated with mortality in this group of patients [28]. (прошлая версия): Pro-inflammatory cytokines tumor necrosis factor (TNF)-α, interleukin (IL)-1 and IL-6 play an important role in the pathogenesis of heart failure.…”

Section: Commented [1]: Describe Ferritin Data??mentioning

confidence: 99%

Cardiac Biomarkers of High Risk of Complications and Death in Patients with SARS-COV-2 and CHF

Glavatskikh¹,

Budnevsky²,

Tokmachev³

et al. 2022

PJMHS

View full text Add to dashboard Cite

The review is devoted to investigate cardiovascular biomarkers in patients with SARS-CoV-2 associated with a high risk of complications and death. The article provides information on the main cardiovascular biomarkers and pro-inflammatory cytokines in relations to the processes of decompensation in patients with chronic heart failure complicated by ARVI, including the SARS-CoV-2. MeSHwords: heart failure, troponin I, NT-proBNP, cytokines, SARS-CoV-2

show abstract

Section: Commented [1]: Describe Ferritin Data??mentioning

confidence: 99%

Cardiac Biomarkers of High Risk of Complications and Death in Patients with SARS-COV-2 and CHF

Glavatskikh¹,

Budnevsky²,

Tokmachev³

et al. 2022

PJMHS

View full text Add to dashboard Cite

show abstract

“…К наиболее значимым механизмам декомпенсации ХСН при инфицировании вирусом SARS-CoV-2 относят: негативное влияние лихорадки любого происхождения на водно-солевой обмен и увеличение нагрузки на сердце; повреждение мио карда, опосредованное избыточной активацией цитокинов; прямое действие вируса на кардиомиоциты с развитием миокардита [2]. Значимость вклада имеющейся органической патологии сердца в контексте легочных осложнений COVID-19 варьирует от наличия классической ХСН с сохраненной фракцией выброса левого желудочка (ФВ ЛЖ) до развития острой систолической сердечной недостаточности как патологического ответа на цитокиновую фазу течения COVID-19.…”

Section: ключевые моменты что известно о предмете исследования?unclassified

“…Значимость вклада имеющейся органической патологии сердца в контексте легочных осложнений COVID-19 варьирует от наличия классической ХСН с сохраненной фракцией выброса левого желудочка (ФВ ЛЖ) до развития острой систолической сердечной недостаточности как патологического ответа на цитокиновую фазу течения COVID-19. После перенесенной COVID-19 у большинства пациентов наблюдается декомпенсация ХСН, что связывают с возникновением фиброзных изменений в легочной ткани и миокарде [2].…”

Section: ключевые моменты что известно о предмете исследования?unclassified

Effect of spironolactone therapy on the activity of the matrix metalloproteinase system in patients with heart failure after COVID-19

Подзолков

Тарзиманова

Брагина

et al. 2022

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To assess the change in the activity of the matrix metalloproteinase (MMP) system after 6-month spironolactone therapy in patients with heart failure (HF) with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF) after coronavirus disease 2019 (COVID-19).Material and methods. The study included 90 patients treated at the University Clinical Hospital № 4 of the I.M. Sechenov First Moscow State Medical University with a laboratory-confirmed COVID-19. There were following inclusion criteria: age of 18-85 years; the presence of HFpEF and HFmrEF. The patients were randomized into two groups: group I (n=60) — patients with 6-month spironolactone therapy (25 mg/day) in addition to the standard therapy for HF, spironolactone was taken at a dose of 25 mg/day; Group II (comparison group, n=30) — patients who received standard therapy without spironolactone. All patients were determined plasma MMP concentrations.Results. There were no significant differences in the levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) between the groups when included in the study. A repeated investigation revealed a significant decrease in the concentrations of MMP-9 and TIMP-1 only in group I. In patients of group II, there were no significant changes in the plasma concentrations of MMP-9 and TIMP-1. The MMP-9/TIMP-1 ratio during the initial examination of patients did not have significant differences. After 6-months therapy, a significant decrease in the ratio of MMP-9/TIMP-1 was observed only in patients taking spironolactone.Conclusion. The results obtained confirm a significant decrease in MMP system activity after 6-month spironolactone therapy in patients with HFpEF and HFmrEF after COVID-19. The described antifibrotic effects of spironolactone make it possible to recommend the use of this drug in this category of patients to reduce the negative effect of MMPs on cardiovascular system.

show abstract

“…In addition, an increase in the incidence of cardiovascular events after recovery from COVID-19 may also play a role in the increase in mortality [6,7,8].…”

Section: Relevance Of the Problemmentioning

confidence: 99%

Features of the course of cardiovascular diseases against the background of COVID-19

Betuganova¹,

Notov²,

Ahkubekova³

et al. 2022

View full text Add to dashboard Cite

show abstract

COVID-19 and cardiovascular diseases

Cited by 11 publications

References 12 publications

Cardiac Biomarkers of High Risk of Complications and Death in Patients with SARS-COV-2 and CHF

Cardiac Biomarkers of High Risk of Complications and Death in Patients with SARS-COV-2 and CHF

Effect of spironolactone therapy on the activity of the matrix metalloproteinase system in patients with heart failure after COVID-19

Features of the course of cardiovascular diseases against the background of COVID-19

Contact Info

Product

Resources

About